Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/8/2025

Cytomegalovirus Infection Treatment

Introduction to Treatment

  • The Centers for Disease Control and Prevention (CDC) recommends valganciclovir oral 900 mg once a day for maintenance treatment, with a strength of evidence not specified 1

Induction and Maintenance Therapy

  • The CDC recommends valganciclovir 900 mg once a day for maintenance treatment, following induction with 900 mg twice a day for 2-3 weeks, with a strength of evidence not specified 1
  • Maintenance treatment is recommended for life, unless there is immune reconstitution with HAART (CD4+ >100-150 cells/μL for >6 months), with a strength of evidence not specified 1
  • For leukemia patients with CMV gastritis, treatment with intravenous ganciclovir 5 mg/kg twice daily for 2-3 weeks, followed by oral valganciclovir 900 mg twice daily, is recommended until CMV is no longer detectable, as per the National Comprehensive Cancer Network guidelines 2, 3, 4, 5
  • Alternative first-line treatment options include intravenous ganciclovir 5 mg/kg IV twice daily for 2-3 weeks and valganciclovir 900 mg PO twice daily for 2-3 weeks (if oral intake is possible), according to the National Comprehensive Cancer Network 2, 5
  • Foscarnet can be used as an alternative at a dose of 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours for 2-3 weeks, as recommended by the National Comprehensive Cancer Network 2, 5, 4
  • For severe cases, especially with CNS involvement, a combination of ganciclovir (5 mg/kg IV every 12 h) and foscarnet (60 mg/kg IV every 8 h or 90 mg/kg IV every 12 h) for 3 weeks is recommended, with a response rate of 74% in patients with CMV encephalitis or myelitis, according to the National Comprehensive Cancer Network 4
  • Maribavir can be considered for CMV infections refractory to ganciclovir/valganciclovir, foscarnet, or cidofovir, with infectious disease consultation recommended due to potential drug resistance, as suggested by the National Comprehensive Cancer Network 2

Special Populations

  • The CDC recommends valganciclovir 900 mg once a day for patients with a history of transplantation, with a strength of evidence not specified, although specific details on the type of transplantation are not provided in the associated citation 1
  • Patients with neutropenia should be treated with caution when using ganciclovir due to myelosuppressive effects, as recommended by the National Comprehensive Cancer Network 2
  • Dose adjustment is required for both ganciclovir and foscarnet in patients with renal dysfunction, as recommended by general medical practice
  • Patients with hepatic dysfunction may have reduced efficacy with oral valganciclovir due to decreased conversion to active form, as noted by the National Comprehensive Cancer Network 2
  • Patients with gastrointestinal GVHD may prefer intravenous therapy over oral valganciclovir, as recommended by the National Comprehensive Cancer Network 2

Monitoring and Side Effects

  • CMV viral load should be monitored weekly to evaluate treatment response, as recommended by general medical practice and the National Comprehensive Cancer Network 2
  • Complete blood counts should be monitored twice weekly during induction therapy, then weekly, to assess for potential toxicities such as neutropenia and thrombocytopenia, as recommended by general medical practice
  • Renal function should be monitored before each foscarnet infusion or twice weekly with ganciclovir, and serum electrolytes should be monitored twice weekly, especially with foscarnet use, to assess for potential nephrotoxicity and electrolyte abnormalities, as recommended by general medical practice
  • Patients should be monitored daily for bleeding manifestations, signs of electrolyte abnormalities, and nephrotoxicity, with aggressive replacement of calcium, magnesium, and potassium as needed, as recommended by the CDC and the National Comprehensive Cancer Network 6
  • Foscarnet can cause significant renal dysfunction in approximately 25% of patients, and careful monitoring of renal function and appropriate hydration are essential, as reported by the CDC and the German Society of Hematology and Medical Oncology (DGHO) 7, 8
  • Ganciclovir/Valganciclovir may cause neutropenia, thrombocytopenia, anemia, and renal dysfunction, as reported by the CDC 6, 9
  • Cidofovir can cause nephrotoxicity, neutropenia, and metabolic acidosis, as reported by the CDC 9

Prevention and Immune System Maintenance

  • The best prevention of CMV disease is maintaining a healthy immune system through effective treatment, as suggested by the CDC 9
  • Always attempt to decrease immunosuppression whenever possible, with a strength of evidence of BIII, as recommended by the CDC and the National Comprehensive Cancer Network 6, 4
  • Maintenance therapy should be considered for patients with compromised immune systems until immune recovery occurs, according to the CDC 9
  • Initiate appropriate antiretroviral therapy (ART) for patients with acute CMV infections, as recommended by the CDC 9
  • For neurological disease, consider delaying ART until clinical improvement occurs to avoid inflammatory reactions (CIII), according to the CDC 9

REFERENCES